Healthy.io is a health-tech company with a mission to improve healthcare outcomes by turning the smartphone into a regulatory approved clinical device. Its first product line, Dip.io, allows patients to do regular urine tests at home using their smartphone cameras and a digital testing kit and measures 10 parameters, indicating a range of infections, chronic illnesses and pregnancy-related complications.
Find your nearest AHSN
With 42m urine tests undertaken by the NHS, urinalysis is the second most common diagnostic test. It is possible to use this technology across a huge range of clinical pathways, for example, the team are working with the East Midlands AHSN on moving Urinary Tract Infection (UTI) testing out of GP clinic and into the community pharmacy setting to reduce pressure on general practice. They are also working with maternity services to offer generic urine testing for pregnant women that need frequent testing but are low risk and therefore don’t need to keep attending clinic to complete the tests.
Dip.io is being used as part of a project at Salford Royal NHS Foundation Trust, Manchester, where patients who are particularly prone to developing UTIs are given kits to take at home when they develop symptoms. The technology aims to speed up diagnosis, treatment and has prevented hospital admission in some cases.
This product is extremely user-friendly, giving patients the confidence to self-manage their condition. Feedback from patients has been extremely positive with a score of 88 being reported by the Net Promoter tool analysing client experience and loyalty – in an environment where over 70 is considered world-class.
This technology has been particularly useful during the Covid-19 outbreak.
Olivia Hind, Partnerships Director at Healthy.io comments on her relationship with the AHSNs:
"The economic evaluation supported by Yorkshire & Humber AHSN has helped us to build a healthcare economic case and go to other areas demonstrating the financial savings and usability. It has also helped us build up our business case as we expand into the US.
The AHSNs helped us to understand which care pathways to focus on, which geographical areas, which customers - whether it’s Clinical Commissioning Groups or Trusts, and that’s enabled us to fine tune our offering and products and secure additional NHS contracts."
How did the Innovation Exchange help?
Healthy.io has worked closely with a number of AHSNs - Health Innovation Manchester, North East North Cumbria, East Midlands, UCL Partners, Kent, Surrey, Sussex and Yorkshire & Humber AHSN.
This product is extremely user-friendly, giving patients the confidence to self-manage their condition. Initial feedback from patients has been extremely positive with a score of 88 being reported by the Net Promoter tool analysing client experience and loyalty – in an environment where over 70 is considered world-class.
The company is one of four companies selected to help improve care in the NHS as part of the Greater Manchester Digital Health Accelerator. The Greater Manchester Digital Accelerator is supporting Healthy.io to grow, prove the benefits of the product and get further exposure and introductions within the NHS. Healthy.io is particularly interested in engaging with programmes of work in Maternity, Pre-operative assessment, recurrent UTI patients, prevention/screening for Chronic Kidney Disease.
The Yorkshire & Humber AHSN commissioned York Health Economic Consortium to evaluate the cost-effectiveness of the service for people with diabetes and hypertension that did not comply with traditional annual testing.
Impact & Outcomes
The York Health Economic Consortium's economic report stated that by rolling out this innovation for non-compliant at-risk populations (people with diabetes or hypertension) across England, an estimated 11,376 cases of end-stage renal disease (ESRD), and 1361 deaths would be prevented over 5 years due to 33,723 additional cases of Chronic Kidney Disease being diagnosed, potentially saving the NHS £660,000,000.
In 2019, Healthy.io received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its smartphone-based ACR test to be used in the aid of diagnosing chronic kidney disease (CKD), which affects over 35 million Americans. This is the second FDA clearance the company has received. The company also closed a $60 million Series C funding round led by Corner Ventures with participation by Joy Capital and all previous investors: Ansonia Holdings, Aleph, and Samsung NEXT.
In 2020, Healthy.io was awarded funding as part of a £150,000 'call to action' for new and innovative ways to use digital technology in response to coronavirus and 'beyond'. The selected technology was a wound assessment app called SPOT which enables image capturing and semi-automatic in-app measurements via a smartphone camera. The system aims to scan wounds with a dedicated app, the images are then normalised and shared on a secure digital portal which can be viewed by tissue viability nurses, district nurses and GPs.
The company has also been listed on CNBC's 2020 Disruptor 50 list.